Best Of ASCO 2025, Seattle - Enduring Recorded Webcast

This accredited continuing education activity, Best of ASCO 2025, Seattle - Enduring Recorded Webcast, is recorded from the live conference held from 6/13/2025 to 6/14/2025

If you participated in the live conference titled - Best of Asco 2025 , Seattle from 6/13/2025 to 6/14/2025 and claimed CME credits/MOC points for that activity, you do not qualify for CME credits/MOC points for your participation in this enduring activity. This is recorded content from that conference from 6/13/2025 to 6/14/2025. However, you can still enroll in this activity and review the contents as needed.

This recorded webcast, Best of ASCO 2025, Seattle, is designed to improve the care of cancer patients by educating clinicians involved in cancer care. This program includes in-depth discussion and analysis of the latest scientific findings and practice-changing advances in the field. Expert faculty will place abstract findings from ASCO2025 into clinical contexts and discuss how the results may change the current standard of care. This conference is designed to provide physicians, physician assistants, nurse practitioners, pharmacists, nurses, and other healthcare professionals with the latest updates in the field. It will highlight a multidisciplinary approach and the integration of new advances in patient-centered care.

Best of ASCO 2025, Seattle is an accredited continuing education activity (CME activity) that fostered collaborative interdisciplinary interactions and partnerships to stimulate the development of new research and clinical practices that reduce cancer health disparities and improve outcomes of the diverse patient population.

REGISTRATION FEES:

This activity is free for all. 

Target Audience

  • Medical oncologists
  • Radiation oncologists
  • Surgical oncologists
  • Oncology residents/fellows
  • Oncology NPs/PAs
  • Oncology pharmacists
  • Oncology nurses

Organizing Committee 

Course Director:

  • Binay Shah, MD, MHA - Binaytara

Conference Chair:

  • Petros Grivas, MD, PhD - Fred Hutchinson Cancer Center, University Of Washington
  • David Zhen , MD - Fred Hutchinson Cancer Center , University Of Washington

Learning Objectives

Upon successful completion of this educational activity, participants will be able to:

  1. Discuss new and updated treatment options for patients with hematologic malignancies and solid tumors
  2. Identify side effects, indications, and contra-indications of therapies used to diagnose and treat cancers
  3. Explain how to effectively manage side-effects associated with cancer treatment
  4. Review abstracts presented at ASCO® 2025 and discuss their application in clinical settings
Course summary
Available credit: 
  • 10.50 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 10.50 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 10.50 AMA PRA Category 1 Credit™

    The Binaytara is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara designates this live activity for a maximum of 10.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 10.50 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.

  • 0.00 Attendance
  • 10.50 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 10.50 Contact Hours.
Course opens: 
06/13/2025
Course expires: 
06/14/2026
Cost:
$0.00

This educational activity features recorded videos from the live webinar titled Best of ASCO 2025 , Seattle
held on June 13th - 14th, 2025.

The videos are placed in the following order. Feel free to view the content that is relevant to you.

Participants should claim continuing education credits to the extent of their participation.

1 hour and 30 minutes: Session 1 - Hematologic Malignancies

Session Chair: Livia Hegerova, MD

MDS/Leukemias - Roland Walter, MD, PhD, MS

Multiple Myeloma - Danai Dima, MD

Lymphoma & CLL - David Aboulafia, MD

1 hour and 40 minutes : Session 2 - General Oncology

Session Chair: Nellowe Candelario, MD

Sarcoma - Min S. Park, MD

Cutaneous Malignancies - Shailender Bhatia, MD

Advances in CNS Tumor - Vyshak Venur, MD

Management of Cervical and Endometrial Cancers - Recent Updates - Elise J. Simons, MD, FACOG

45 minutes: Session 3 - Tumor-Board Style Discussion: Challenging Cases

Session Chair: Elise J. Simons, MD, FACOG

Case-Based Discussion: Chirag A. Shah, MD MPH

Panel Discussion

1 hour and 30 minutes: Session 4 - Genitourinary Cancer

Session Chair: Petros Grivas, MD, PhD

Prostate Cancer - Hiba Khan, MD, MPH

Bladder Cancer - Rosa Nadal Rios, MD, PhD

Kidney Cancer - Lisa Tachiki, MD

1 hour and 30 minutes: Session 5 - Gastrointestinal Cancer

Session Chair: David B. Zhen, MD

Upper GI Cancer - David B. Zhen, MD

Hepatobiliary and Pancreatic Malignancies - Gentry King, MD

Colorectal Cancer - Stacey Cohen, MD

1 hour and 30 minutes : Session 6 - Breast Cancer

Session Chair: Xiaowen Wang, MD, PhD

Early-Stage Breast Cancer - William Rayford Gwin III, MD

 Metastatic Breast Cancer 1: Metastatic Hormone Receptor-Positive HER2 Negative - Christos Vaklavas, MD

Metastatic Breast Cancer 2: HER2-Positive and Triple-Negative Breast Cancer - Vidhya Nair, DO

45 minutes : Session 7 - Tumor-Board Style Discussion: Challenging Cases

Session Chair: Tanya A. Wahl, MD

Case-Based Discussion: Sid Devarakonda, MD; Ronan Hsieh, MD

Panel Discussion: Joseph Rosales, MD; Lei Deng, MD; Shih-Li (Bruce) Lin, MD

1 hour and 30 minutes: Session 8 - Thoracic Oncology

Session Chair: Keith D. Eaton, MD, PhD

Early-Stage Non-Small Cell Lung Cancer - Nicholas P. Giustini, MD

Metastatic Non-Small Cell Lung Cancer - Lei Deng, MD

Small Cell Lung Cancer - Diane Tseng, MD, PhD

IDENTIFICATION AND MITIGATION OF POTENTIAL CONFLICT OF INTERESTS:

All conflict of interest has been identified and mitigated for individuals in control of contents.

PLANNING COMMITTEE DISCLOSURE STATEMENT:

None of the members of the planning committee, nor any member of their immediate families, have a relevant financial interest in or affiliation with any commercial supporter of this educational activity and/or with the manufacturer(s) of commercial products and/or providers of any commercial services discussed in this educational activity.

Course Director(s)

Binay Shah, MD, MHA has no relevant financial relationships to disclose at this time.

Conference Chair(s)

Petros Grivas, MD, PhD 

has a financial relationship (Professional Services) with Merck;

financial relationship (Professional Services) with BMS;

financial relationship (Professional Services) with AstraZeneca;

financial relationship (Professional Services) with EMD Serano;

financial relationship (Professional Services) with Seattle Genetics;

financial relationship (Professional Services) with Pfizer;

financial relationship (Professional Services) with Janssen;

financial relationship (Professional Services) with Roche;

financial relationship (Professional Services) with Astellas Pharma;

financial relationship (Professional Services) with Gilead Sciences;

financial relationship (Professional Services) with BostonGene;

financial relationship (Professional Services) with Fresenius Kabi;

financial relationship (Professional Services) with Lucence Health;

financial relationship (Professional Services) with PureTech;

financial relationship (Professional Services) with G1 Therapeutics;

financial relationship (Professional Services) with Aadi Biosciences;

financial relationship (Professional Services) with CG Oncology;

financial relationship (Professional Services) with Strata Oncology;

financial relationship (Professional Services) with Immunity Bio;

financial relationship (Professional Services) with Asieris Pharmaceuticals;

financial relationship (Professional Services) with Abbvie;

financial relationship (Grant Or Contract) with Pfizer;

financial relationship (Grant Or Contract) with BMS;

financial relationship (Grant Or Contract) with Merck;

financial relationship (Grant Or Contract) with QED Therapeutics;

financial relationship (Grant Or Contract) with GlaxoSmithKline;

financial relationship (Grant Or Contract) with Mirati Therapeutics;

financial relationship (Grant Or Contract) with EMD Serano;

financial relationship (Grant Or Contract) with G1 Therapeutics;

financial relationship (Grant Or Contract) with Gilead Sciences;

financial relationship (Grant Or Contract) with Acrivon Therapeutics;

financial relationship (Grant Or Contract) with ALX Oncology;

financial relationship (Grant Or Contract) with Genentech.

David Zhen, MD

has a financial relationship (Professional Services) with Merck;

financial relationship (Professional Services) with Bristol Meyers Squibb;

financial relationship (Independent contractor) with Jazz Pharmaceuticals/Zymeworks, Inc;

financial relationship (Professional Services) with A2 Biotherapies;

financial relationship (Professional Services) with Excelixis;

financial relationship (Professional Services) with Ipsen;

financial relationship (Professional Services) with Jazz Pharmaceuticals;

financial relationship (Professional Services) with Medigene;

Financial relationship (Professional Services) with AstraZeneca;

financial relationship (Professional Services) with Bayer;

financial relationship (Professional Services) with Cornerstone Pharmaceuticals;

financial relationship (Professional Services) with Daiichi Sankyo, Inc;

financial relationship (Professional Services) with Eli Lilly;

financial relationship (Professional Services) with Legend Biotech;

financial relationship (Professional Services) with Roche/Genentech;

financial relationship (Professional Services) with Pfizer/Seagen.

Session Chair(s)

Nellowe Candelario 

has no relevant financial relationships to disclose at this time.

Keith Eaton, MD, PhD

has no relevant financial relationships to disclose at this time.

Livia Hegerova 

has a financial relationship (Grant Or Contract) with Sanofi;

financial relationship (Grant Or Contract) with Agios;

financial relationship (Grant Or Contract) with Rigel.

Tanya Wahl, Medical Oncologist, Medical Director Providence Swedish Cancer Institute Issaquah

has no relevant financial relationships to disclose at this time.

Xiaowen Wang 

has no relevant financial relationships to disclose at this time.

Speaker/Topic Presenter(s)

David Aboulafia, MD

has no relevant financial relationships to disclose at this time.

Shailender Bhatia, MD

has a financial relationship (Grant Or Contract) with Agenus;

financial relationship (Grant Or Contract) with Bristol Meyers Squibb;

financial relationship (Grant Or Contract) with Regeneron (fka Checkmate Pharmaceuticals);

financial relationship (Grant Or Contract) with EMD Serono;

financial relationship (Grant Or Contract) with Incyte;

financial relationship (Grant Or Contract) with Merck;

financial relationship (Grant Or Contract) with Trisalus Life Sciences;

financial relationship (Professional Services) with BMS;

financial relationship (Professional Services) with Replimune;

financial relationship (Professional Services) with Regeneron.

Stacey Cohen 

has a financial relationship (Independent contractor) with Abbvie;

financial relationship (Independent contractor) with Agenus;

financial relationship (Independent contractor) with Delcath;

financial relationship (Independent contractor) with Pfizer;

financial relationship (Independent contractor) with Taiho;

financial relationship (Independent contractor) with Guardant;

financial relationship (Independent contractor) with Merck;

financial relationship (Independent contractor) with Regeneron;

financial relationship (Independent contractor) with Exact Sciences;

financial relationship (Independent contractor) with Incyte.

Lei Deng, MD

has a financial relationship (Travel) with MJH Life Sciences;

financial relationship (Independent contractor) with Bristol Meyer Squibb;

financial relationship (Independent contractor) with Regeneron;

financial relationship (Travel) with Merck;

financial relationship (Independent contractor) with Bristol Meyer Squibb;

financial relationship (Grant Or Contract) with BridgeBio Oncology Therapeutics.

Danai Dima, MD

has no relevant financial relationships to disclose at this time.

Nicholas Giustini, MD

has a financial relationship (Other) with Curio Science.

William Gwin 

has a financial relationship (Other) with Astra Zeneca;

financial relationship (Other) with Gilead;

financial relationship (Grant Or Contract) with Astra Zeneca;

financial relationship (Grant Or Contract) with Veanna Therapeutic;

financial relationship (Grant Or Contract) with Amazon.

Hiba Khan, MD, MPH

has no relevant financial relationships to disclose at this time.

Gentry George King, MD

has no relevant financial relationships to disclose at this time.

Rosa Nadal Rios, Associate Professor.  Division of Hematology and Oncology. University of Washington School of Medicine

has no relevant financial relationships to disclose at this time.

Vidhya Nair, DO

has no relevant financial relationships to disclose at this time.

Min Park, MD, MS

has a financial relationship (Stock) with Eli Lilly;

financial relationship (Stock) with Johnson & Johnson;

financial relationship (Stock) with Thermo Fisher Scientific.

Elise Simons, Clinical Assistant Professor, Division of Gynecologic Oncology, University of Washington

has no relevant financial relationships to disclose at this time.

Lisa Tachiki, MD

has no relevant financial relationships to disclose at this time.

Christos Vaklavas, M.D., Associate Professor

has a financial relationship (Employment) with Flatiron;

financial relationship (Professional Services) with Guidepoint;

financial relationship (Professional Services) with Novartis;

financial relationship (Professional Services) with SeaGen;

financial relationship (Professional Services) with Gilead;

financial relationship (Professional Services) with AstraZeneca;

financial relationship (Professional Services) with AstraZeneca;

financial relationship (Financial Support) with Pfizer;

financial relationship (Financial Support) with SeaGen;

financial relationship (Financial Support) with H3 Biomedicine;

financial relationship (Financial Support) with AstraZeneca;

financial relationship (Financial Support) with CytomX.

Roland Walter, MD PhD MS

has a financial relationship (Grant Or Contract) with Celgene/Bristol Myers Squibb;

financial relationship (Grant Or Contract) with ImmunoGen/AbbVie;

financial relationship (Grant Or Contract) with Janssen;

financial relationship (Grant Or Contract) with Pfizer;

financial relationship (Grant Or Contract) with Jazz;

financial relationship (Grant Or Contract) with Kura.

David Zhen, MD

has a financial relationship (Professional Services) with Merck;

financial relationship (Professional Services) with Bristol Meyers Squibb;

financial relationship (Independent contractor) with Jazz Pharmaceuticals/Zymeworks, Inc;

financial relationship (Professional Services) with A2 Biotherapies;

financial relationship (Professional Services) with Excelixis;

financial relationship (Professional Services) with Ipsen;

financial relationship (Professional Services) with Jazz Pharmaceuticals;

financial relationship (Professional Services) with Medigene;

financial relationship (Professional Services) with AstraZeneca;

financial relationship (Professional Services) with Bayer;

financial relationship (Professional Services) with Cornerstone Pharmaceuticals;

financial relationship (Professional Services) with Daiichi Sankyo, Inc;

financial relationship (Professional Services) with Eli Lilly;

financial relationship (Professional Services) with Legend Biotech;

financial relationship (Professional Services) with Roche/Genentech;

financial relationship (Professional Services) with Pfizer/Seagen.

Case Presenter(s)

Sid D 

has a financial relationship (Professional Services) with AZ;

financial relationship (Professional Services) with Lilly;

financial relationship (Professional Services) with Johnson and Johnson;

financial relationship (Grant Or Contract) with AZ;

financial relationship (Professional Services) with Nuvation;

financial relationship (Professional Services) with Takeda;

financial relationship (Professional Services) with Oncohost;

financial relationship (Professional Services) with Acrotech;

financial relationship (Professional Services) with Caris;

financial relationship (Professional Services) with BI;

financial relationship (Professional Services) with Daiichi Sankyo;

financial relationship (Professional Services) with Catalyst.

Ronan Hsieh, MD, MS

has a financial relationship (Financial Support) with Curio Science;

financial relationship (Professional Services) with Bristol Myers Squibb;

financial relationship (Professional Services) with Bayer;

financial relationship (Professional Services) with Janssen;

financial relationship (Travel) with Medscape;

financial relationship (Travel) with Merck.

Bruce Lin, Medical Oncologist

has a financial relationship (Grant Or Contract) with Exelixis;

financial relationship (Grant Or Contract) with Jazz Pharmaceuticals;

financial relationship (Grant Or Contract) with Incyte;

financial relationship (Grant Or Contract) with Relay Therapeutics;

financial relationship (Grant Or Contract) with Merck;

financial relationship (Grant Or Contract) with Tvardi Therapeutics;

financial relationship (Grant Or Contract) with Genentech;

financial relationship (Grant Or Contract) with Cardiff Oncology.

Joseph Rosales, MD

has no relevant financial relationships to disclose at this time.

Chirag Shah, MD MPH

has a financial relationship (Professional Services) with Glaxo Smith Kline;

financial relationship (Professional Services) with Pfizer;

financial relationship (Professional Services) with Abbvie;

financial relationship (Professional Services) with Natera.

Important Information about Claiming CME for this activity:

If you participated in the live course titled - Best of ASCO 2025 ,Seattle on 06/13/2025 - 6/14/2025 and claimed CME credits/MOC points for that activity, you do not qualify for CME credits/MOC points for your participation in this enduring activity. This was recorded from the live course on 06/13/2025 - 6/14/2025

Available Credit

  • 10.50 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 10.50 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 10.50 AMA PRA Category 1 Credit™

    The Binaytara is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara designates this live activity for a maximum of 10.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 10.50 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.

  • 0.00 Attendance
  • 10.50 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 10.50 Contact Hours.

Price

Cost:
$0.00
Please login or register to take this course.

REGISTRATION FEES:

This activity is free for all